Meetings - The ASCO Post

Despite advances in targeted therapies for hematologic malignancies, drug resistance and persistent side effects continue to challenge clinicians and limit patient outcomes, underscoring the urgent ne...

Leukemia

By Caroline Helwick / August 25, 2024 / 2024 Pan Pacific Lymphoma Conference

What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?

Is the optimal first-line treatment of chronic lymphocytic leukemia (CLL) monotherapy with a Bruton’s tyrosine kinase (BTK) inhibitor or some combination regimen? This clinical question was explored b...

Lymphoma

By Caroline Helwick / September 10, 2024 / 2024 Pan Pacific Lymphoma Conference

Extranodal Marginal Zone Lymphoma: Is Overtreatment Common?

Most patients with extranodal marginal zone lymphoma (MZL) are overtreated, according to Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and Institute of Oncology Research in Bel...

2024 Pan Pacific Lymphoma Conference

BTK Degraders and CELMoDs: Novel Mechanisms Overcoming Resistance in Hematologic Malignancies

What Is the Optimal First-Line Therapy for Chronic Lymphocytic Leukemia?

Extranodal Marginal Zone Lymphoma: Is Overtreatment Common?

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC